Opinion|Videos|December 18, 2024
Frontline Treatment Options for LR-MDS Beyond ESAs
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss how the NCCN Guidelines define lower-risk myelodysplastic syndrome (LR-MDS) based on clinical hallmarks such as anemia and cytopenias, with treatment decisions guided by prognostic scoring systems (IPSS-R, IPSS-M), and how real-world data supports the evolving first-line treatment landscape for LR-MDS, including the use of therapies such as luspatercept.
Episodes in this series
- Please provide a brief overview of LR-MDS per
NCCN Guidelines .- Briefly describe clinical hallmarks that lead to an MDS diagnosis.
- What are the available treatments for anemia in patients with LR-MDS?
- With treatment decisions for LR-MDS, how do you incorporate prognostic scoring systems (IPSS-R, IPSS-M) in the first-line decision-making process?
- Please elaborate on how these scoring systems influence the choice between available options.
- Please discuss the real-world data related to first-line treatment options for LR-MDS (
Fonseca et al, MDS #276 SOHO 2024 ;Garcia-Manero et al, Clin Lymph Myel Leuk 2024 ).- Please elaborate on how this evidence supports the changing landscape for first-line treatment for lower-risk MDS.
Related Content
Advertisement
